Lyra touts pos­i­tive topline PhII da­ta for chron­ic rhi­nos­i­nusi­tis drug

Lyra Ther­a­peu­tics de­buted pos­i­tive topline da­ta this morn­ing for one of its lead pro­grams, LYR-220, which aims to treat chron­ic rhi­nos­i­nusi­tis in pa­tients who still have the dis­ease even af­ter si­nus surgery.

The com­pa­ny said it met the Phase II tri­al’s pri­ma­ry end­point and showed sta­tis­ti­cal­ly sig­nif­i­cant im­prove­ment through the 24-week tri­al. The pri­ma­ry end­point was safe­ty, with no se­ri­ous ad­verse events re­port­ed. The most com­mon­ly re­port­ed ad­verse events were si­nusi­tis, na­sopharyn­gi­tis, bron­chi­tis and Covid-19.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER